Keyphrases
Adrenal Suppression
100%
Combination Chemotherapy
100%
Hormone-sensitive Prostate Cancer
100%
Chemotherapy
50%
Vinblastine
50%
Estramustine
50%
Prostate-specific Antigen
33%
Conventional Chemotherapy
16%
Soft Tissue
16%
Median Survival
16%
Prostate Cancer
16%
No Response
16%
Survival Rate
16%
Antiandrogen
16%
Objective Response
16%
Soft Tissue Disease
16%
Androgen-independent
16%
Androgen Suppression
16%
Hormone Refractory
16%
Medicine and Dentistry
Adrenal Suppression
100%
Androgen
100%
Prostate Cancer
100%
Combination Chemotherapy
100%
Vinblastine
50%
Estramustine
50%
Prostate Specific Antigen
33%
Survival Rate
16%
Castration Resistant Prostate Cancer
16%
Androgen Suppression
16%
Antiandrogen
16%
Soft Tissue Disease
16%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Prostate Cancer
100%
Androgen
100%
Vinblastine
42%
Estramustine
42%
Prostate Specific Antigen
28%
Survival Rate
14%
Castration Resistant Prostate Cancer
14%
Antiandrogen
14%
Soft Tissue Disease
14%
Neuroscience
Prostate
100%
Androgen
100%
Vinblastine
42%
Estramustine
42%
Prostate Specific Antigen
28%
Antiandrogen
14%
Biochemistry, Genetics and Molecular Biology
Adrenal Suppression
100%
Estramustine
60%
Prostate-Specific Antigen
40%
Survival Rate
20%